ArticlemBio2014
Acellular pertussis vaccines and pertussis resurgence: revise or replace?
Article in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 62 citations in OpenAlex.
- Allele-Skewed HLA-DR Immunopeptidomes ofVaccines · 2026Article
- Global, regional, and national burden of pertussis in children aged 0-14 years from 1990 to 2021: A systematic analysis of the Global Burden of Disease Study 2021.Infectious diseases & immunity · 2026Article
- Programming Bordetella pertussis lipid A to promote adjuvanticity.Microbial cell factories · 2024Article
- Genome-based prediction of cross-protective, HLA-DR-presented epitopes as putative vaccine antigens for multipleMicrobiology spectrum · 2024Article
- Review
- Article
- Prior exposure to B. pertussis shapes the mucosal antibody response to acellular pertussis booster vaccination.Nature communications · 2022Article
- Characterization ofPathogens (Basel, Switzerland) · 2022Article
- Immunogenicity of a Candidate DTacP-sIPV Combined Vaccine and Its Protection Efficacy against Pertussis in a Rhesus Macaque Model.Vaccines · 2021Article
- Modeling Immune Evasion and Vaccine Limitations by Targeted Nasopharyngeal Bordetella pertussis Inoculation in Mice.Emerging infectious diseases · 2021Article
- Fha DeficientIranian journal of public health · 2021Article
- Genomic Surveillance and Improved Molecular Typing of Bordetella pertussis Using wgMLST.Journal of clinical microbiology · 2021Article
- Recent increase in pertussis incidence in Korea: an age-period-cohort analysis.Epidemiology and health · 2021Article
- Review
- Pertussis immunization in healthcare workers working in pediatric settings: Knowledge, Attitudes and Practices (KAP) of Occupational Physicians. Preliminary results from a web-based survey (2017).Journal of preventive medicine and hygiene · 2020Article
- Development and Validation of aJournal of immunology research · 2020Article
- Article
- Genomic Survey of Bordetella pertussis Diversity, United States, 2000-2013.Emerging infectious diseases · 2019Article
- Population dynamics and antigenic drift ofEmerging microbes & infections · 2019Article
- Resolving the complex Bordetella pertussis genome using barcoded nanopore sequencing.Microbial genomics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The resurgence of pertussis (whooping cough) in countries with high vaccination coverage is alarming and invites reconsideration of the use of current acellular pertussis (aP) vaccines, which have largely replaced the old, reactogenic, whole-cell pertussis (wP) vaccine. Some drawbacks of these vaccines in terms of limited antigenic composition and early waning of antibody levels could be anticipated by the results of in-trial or postlicensure human investigations of B- and T-cell responses in aP versus wP vaccine recipients or unvaccinated, infected children. Recent data in experimental models, including primates, suggest that generation of vaccines capable of a potent, though regulated, stimulation of innate immunity driving effective, persistent adaptive immune responses against Bordetella pertussis infection should be privileged. Adjuvants that skew Th1/Th17 responses or new wP (detoxified or attenuated) vaccines should be explored. Nonetheless, the high merits of the current aP vaccines in persuading people to resume vaccination against pertussis should not be forgotten.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.